Advertisement
Canada markets open in 3 hours 2 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7262
    -0.0001 (-0.02%)
     

  • CRUDE OIL

    82.30
    -0.43 (-0.52%)
     

  • Bitcoin CAD

    89,354.29
    +4,479.35 (+5.28%)
     

  • CMC Crypto 200

    1,332.81
    +20.19 (+1.56%)
     

  • GOLD FUTURES

    2,396.80
    -1.20 (-0.05%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,439.75
    -107.50 (-0.61%)
     

  • VOLATILITY

    19.11
    +1.11 (+6.17%)
     

  • FTSE

    7,838.59
    -38.46 (-0.49%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6815
    -0.0006 (-0.09%)
     

Endo International (ENDP) Stock Sinks As Market Gains: What You Should Know

Zacks Equity Research
·2 min read

Endo International (ENDP) closed the most recent trading day at $3.27, moving -1.8% from the previous trading session. This change lagged the S&P 500's daily gain of 0.08%. Elsewhere, the Dow lost 0.56%, while the tech-heavy Nasdaq lost 0.28%.

Coming into today, shares of the health care company had lost 10.24% in the past month. In that same time, the Medical sector lost 4.1%, while the S&P 500 gained 0.22%.

Endo International will be looking to display strength as it nears its next earnings release. On that day, Endo International is projected to report earnings of $0.67 per share, which would represent a year-over-year decline of 10.67%. Meanwhile, our latest consensus estimate is calling for revenue of $734.44 million, down 3.39% from the prior-year quarter.

It is also important to note the recent changes to analyst estimates for Endo International. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

ADVERTISEMENT

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 7.31% lower. Endo International currently has a Zacks Rank of #3 (Hold).

In terms of valuation, Endo International is currently trading at a Forward P/E ratio of 1.46. This valuation marks a discount compared to its industry's average Forward P/E of 14.9.

The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 38% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Endo International plc (ENDP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.